Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 15/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350821 | 0.84 | SIGMAR1 (0.48) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| SCHEMBL3223126 | 0.84 | SIGMAR1 (0.48) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| Hydrochloric Acid SCHEMBL349643 | 0.83 | SIGMAR1 (0.47) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| SCHEMBL11829064 | 0.81 | SIGMAR1 (0.51) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| SCHEMBL171980 | 0.80 | SIGMAR1 (0.54) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| SCHEMBL29674557 | 0.80 | SIGMAR1 (0.54) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| Hydrochloric Acid SCHEMBL2002554 | 0.79 | SIGMAR1 (0.52) | SIGMAR1NPY5RAVPR1ATNKSTNKS2 | |
| Hydrochloric Acid SCHEMBL1995606 | 0.78 | SIGMAR1 (0.51) | SIGMAR1NPY5RAVPR1ATNKSTNKS2 | |
| SCHEMBL8777675 | 0.77 | SIGMAR1 (0.61) | SIGMAR1NPY5RCFTRGOPCAVPR1A | |
| SCHEMBL12935304 | 0.76 | SIGMAR1 (0.49) | SIGMAR1NPY5RCFTRGOPCAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | SIGMAR1 3694/4885NPY5R 1609/4885CFTR 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.